摘要
目的:运用网络药理学探讨射麻止喘液治疗哮喘的潜在机制。方法:利用中药分子机制的生物信息学分析工具、中药系统药理数据库和分析平台查找射麻止喘液的成分及其靶点,从比较毒理基因组学数据库(CTD)获取与哮喘相关的基因;将射麻止喘液-基因和哮喘-基因的数据集导入Draw Venn Diagram进行交集分析,得出射麻止喘液-哮喘-基因数据集;使用String 11. 0进行射麻止喘液-哮喘-基因数据集的蛋白质-蛋白质相互作用(PPI)分析,运用Cytoscape 3. 6. 1进行可视化,用其插件MCODE分析重要模块;采用DAVID 6. 8分析射麻止喘液-哮喘-基因的通路富集和生物学过程。结果:获得射麻止喘液399个化合物与2 099个潜在的靶点;同时检索出98个与哮喘相关靶点;应用交集和PPI分析筛选出45个共同基因和关键基因16个,包括转化生长因子-β1,血红素氧合酶-1,白细胞介素-4等;富集分析显示射麻止喘液和哮喘的共同生物学过程与炎症反应、气道的收缩与重塑、细胞增殖与凋亡等相关,共同生物学通路包括肿瘤坏死因子信号通路、免疫球蛋白E(IgE)的高亲和力受体信号通路、核转录因子-κB信号通路、核苷酸结合寡聚化结构域样受体信号通路等。结论:射麻止喘液是通过多靶点、多通路治疗哮喘,可为其深入研究和临床应用提供参考。
Objective:To explore the potential mechanism of Shema Zhichuan liquid in treatment of asthma by network pharmacology.Method:Bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine(TCM),systematic pharmacological database and analysis platform of TCM were employed to find the components in Shema Zhichuan liquid and their targets,and asthma-related genes were obtained from the comparative toxicogenomics database(CTD).The data set of Shema Zhichuan liquid-gene and asthma-gene were imported into the Draw Venn Diagram for intersection analysis.The obtained data set of Shema Zhichuan liquidasthma-gene was imported into String 11.0 for protein-protein interaction(PPI)analysis,and was visualized by Cytoscape 3.6.1,and further important modules were analyzed with MCODE.DAVID 6.8 was used to analyze pathway enrichment and biological process of Shema Zhichuan liquid-asthma-gene.Result:A total of 399 components and 2 099 potential targets were obtained from Shema Zhichuan liquid,98 asthma-related targets were retrieved,45 common genes and 16 hub genes were screened,including transforming growth factor-β1(TGF-β1),heme oxygenase-1(HMOX1),interleukin-4(IL-4),etc.Enrichment analysis showed that the common biological processes of Shema Zhichuan liquid and asthma were related to inflammation,contraction and remodeling of airway,cell proliferation and apoptosis,etc.The common biological pathways mainly included tumor necrosis factor(TNF)signaling pathway,receptor with high affinity for immunoglobulin E(Fc epsilon RI)signaling pathway,nuclear transcription factor-kappa B(NF-κB)signaling pathway,nucleotide binding oligomerization domain(NOD)-like receptor signaling pathway and so on.Conclusion:Shema Zhichuan liquid serves as a multi-target,multi-pathway treatment for asthma,which can provide a reference for the further research and clinical application of this preparation.
作者
黄秀芳
高运吉
廖钢
黄慧婷
詹少锋
赖艳妮
刘小虹
HUANG Xiu-fang;GAO Yun-ji;LIAO Gang;HUANG Hui-ting;ZHAN Shao-feng;LAI Yan-ni;LIU Xiao-hong(The First Clinical Medical College of Guangzhou University of Chinese Medicine,Guangzhou 510405,China;Shenzhen Hospital of Guangzhou University of Chinese Medicine,Shenzhen 518000,China;Guangdong Provincial Inheritance Studio of Famous Traditional Chinese Medicine of LIU Xiao-hong,The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2019年第23期187-195,共9页
Chinese Journal of Experimental Traditional Medical Formulae
基金
广东省自然科学基金项目(2018A030310520)
广州市科技计划项目(201904010235)
广东省中医药局名优中成药二次开发项目(20174007)
作者简介
第一作者:黄秀芳,在读博士,从事中医防治呼吸系统疾病研究,E-mail:879172531@qq.com;通信作者:刘小虹,主任医师,教授,博士生导师,从事中医防治呼吸系统疾病研究,E-mail:rsclxh@gzucm.edu.cn
